S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges

Bibliography

• A study to determine the safety and efficacy of once daily raltegravir compared to twice daily raltegravir (MK-0518-071). Available from: http://clinicaltrials.gov/ct2/show/NCT00745823 [Last accessed 28 October 2010]
   Google Scholar
• Vispo E, Barreiro P, Maida I, Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. HIV Clin Trials 2010;11:197-204
   PubMed Web of Science ®Google Scholar
• Fun A, Van Baelen K, van Lelyveld SF, Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity. J Antimicrob Chemother 2010;65:2300-4
   PubMed Web of Science ®Google Scholar
• Phase 3, randomized, double-blind study to evaluate the safety and efficacy of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 versus efavirenz/emtricitabine/ tenofovir disoproxil fumarate in HIV-1 infected, antiretroviral treatment-naive adults. Available from: http://clinicaltrials.gov/ct2/show/NCT01095796 [Last accessed 24 October 2010]
   Google Scholar
• Study of the safety and efficacy of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 (QUAD) versus atripla(R) in HIV infected, antiretroviral treatment-naive adults. Available from: http://clinicaltrials.gov/ct2/show/NCT00869557 [Last accessed 24 October 2010]
   Google Scholar
• German P, Warren D, West S, Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55:323-9
   PubMed Web of Science ®Google Scholar
• Johns B, Kawasuji T, Taishi T, The Discovery of S/GSK1349572: a once daily next generation integrase inhibitor with a superior resistance profile. 17th Conference on Retroviruses and Opportunistic Infections; 2010; Paper no. 55
   Google Scholar
• Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res 1999;52:351-69
   PubMed Web of Science ®Google Scholar
• Brown PO. Integration of retroviral DNA. Curr Top Microbiol Immunol 1990;157:19-48
   PubMed Web of Science ®Google Scholar
• Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005;4:236-48
   PubMed Web of Science ®Google Scholar
• Li M, Mizuuchi M, Burke TR Jr, Craigie R. Retroviral DNA integration: reaction pathway and critical intermediates. EMBO J 2006;25:1295-304
   PubMed Web of Science ®Google Scholar
• Prada N, Markowitz M. Novel integrase inhibitors for HIV. Expert Opin Investig Drugs 2010;19:1087-98
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Felock P, Witmer M, Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50
   PubMed Web of Science ®Google Scholar
• Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist Updat 2010;13:139-50
   PubMed Web of Science ®Google Scholar
• Kawasuji T, Fuji M, Yoshinaga T, A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors. Bioorg Med Chem 2006;14:8420-9
   PubMed Web of Science ®Google Scholar
• Marchand C, Johnson AA, Karki RG, Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble doublemutant (F185K/C280S). Mol Pharmacol 2003;64:600-9
   PubMed Web of Science ®Google Scholar
• Espeseth AS, Felock P, Wolfe A, HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000;97:11244-9
   PubMed Web of Science ®Google Scholar
• Min S, Song I, Borland J, Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010;54:254-8
   PubMed Web of Science ®Google Scholar
• Min S, Song I, Borland J, Pharmacokinetics (PK) and safety in healthy subjects of S/GSK1349572, a next generation, once-daily HIV integrase inhibitor (INI) [poster No. WEPEA099]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009
   Google Scholar
• Song I, Min S, Borland J, The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharm 2010: published on 20 May 2010, doi:10.1177/0091270010371113
   Google Scholar
• GSK1349572 Mass Balance Study. Available from: http://clinicaltrials.gov/ct2/show/NCT00828763 [Last accessed 15 October 2010]
   Google Scholar
• Song I, Patel A, Min S, Evaluation of antacid and multivitamin (MVI) effects on S/GSK1349572 pharmacokinetics (PK) in healthy subjects [poster No. A1-1305]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009
   Google Scholar
• Patel P, Song I, Borland J, S/GSK1349572, a next generation HIV integrase inhibitor, pharmacokinetics are not affected by omeprazole in healthy adults [abstract No. H-943]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010
   Google Scholar
• Song I, Borland J, Chen S, Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next generation integrase inhibitor, S/GSK1349572 [poster no. 616]. 17th Conference on Retroviruses and Opportunistic Infections; 2010
   Google Scholar
• Song I, Min S, Borland J, Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr 2010: published on 25 June 2010, doi: 10.1097/QAI.0b013e3181e67909
   Google Scholar
• Song I, Min S, Borland J, The effect of etravirine anlone and with boosted protease inhibitors on the pharmacokinetics of the integrase inhibitor, S/GSK1349572 [abstract No. 26]. 11th International Workshop on Clinical Pharmakology of HIV Therapy; 2010
   Google Scholar
• GSK1349572 drug interaction study with efavirenz. Available from: http://clinicaltrials.gov/ct2/show/NCT01098526 [Last accessed 15 October 2010]
   Google Scholar
• Drug interaction study between GSK1349572 and tipranavir/ritonavir in healthy volunteers (ING). Available from: http://clinicaltrials.gov/ct2/show/NCT01068925 [Last accessed 15 October 2010]
   Google Scholar
• GSK1349572 drug interaction study with fosamprenavir/ritonavir. Available from: http://clinicaltrials.gov/ct2/show/NCT01209065 [Last accessed 15 October 2010]
   Google Scholar
• Underwood M, Vavro C, Ptak R, Activity of the next generation integrase inhibitor S/GSK1349572 and two first generation inhibitors across a broad panel of HIV subtype isolates in PBMCs and MDMs [poster No. MOPE0032]. 18th International AIDS Conference; 2010
   Google Scholar
• Sato A, Seki T, Kobayashi M, In vitro passage of drug resistant HIV-1 against a next generation integrase inhibitor (INI), S/GSK1349572 [poster No. H-932]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009
   Google Scholar
• Seki T, Kobayashi M, Wakasa-Morimoto C, S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. 7th Conference on Retroviruses and Opportunistic Infections (CROI); 16 – 19 February 2010; San Francisco
   Google Scholar
• Kobayashi M, Yoshinaga T, Seki T, In vitro virology of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2010. [Epub ahead of print]
   Google Scholar
• Underwood M, Johns B, Sato A, S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy [poster No. WEPEA098]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009
   Google Scholar
• Charpentier C, Larrouy L, Collin G, In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS 2010: published on 4 September 2010, doi: 10.1097/QAD.0b013e32833f9e36
   Google Scholar
• Lalezari J, Sloan L, Dejesus E. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-naive HIV-1-infected patients [abstract No. TUAB105]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009
   Google Scholar
• Song I, Chen S, Lou Y, Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572, a next generation integrase inhibitor (INI), in HIV-1 infected patients [abstract No. WEPEB250]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009
   Google Scholar
• Arribas J, Lazzarin A, Raffi F, Once-daily S/GSK1349572 as part of combination therapy in antiretroviral naive adults: rapid and potent antiviral responses in the interim 16-week analysis from SPRING-1 (ING112276) [abstract No. THLBB205]. 18th International AIDS Conference; 2010
   Google Scholar
• Rockstroh J, Felizarta F, Maggiolo F, Once-daily S/GSK1349572 combination therapy in antiretroviral-naive adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276). J Int AIDS Soc 2010;13(Suppl 4):O50
   PubMed Web of Science ®Google Scholar
• Eron J, Durant J, Poizot-Martin I, Activity of next generation integrase inhibitor (INI) S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961) [abstract No. MOAB0105]. 18th International AIDS Conference; 2010
   Google Scholar
• Eron J, Livrozet JM, Morlat P, Activity of integrase inhibitor, S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of VIKING study (ING112961). J Int AIDS Soc 2010;13(Suppl 4):O51
   PubMed Web of Science ®Google Scholar
• Clotet B, DeJesus E, Lazzarin A, HIV integrase genotypic and phenotypic changes between day 1 and day 11 in subjects with raltegravir resistant HIV treated with S/GSK1349572: results of VIKING study [poster No. TUPE130]. 18th International AIDS Conference; 2010
   Google Scholar
• Clotet B, Katlama C, Lalezari J, HIV integrase resistance profiles and S/GSK1349572 baseline phenotypic susceptibility for subjects experiencing virologic failure on raltegravir (RAL) in the VIKING study (ING112961). International HIV and Hepatitis Drug Resistance Workshop; 8 – 12 June 2010; Dubrovnik Croatia
   Google Scholar
• Lou Y, Min S, Chen I, Meta-analysis of safety for short-term dosing of an HIV Integrase inhibitor, S/GSK1349572, from seven clinical studies [poster No. H-931]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009
   Google Scholar
• Chen S, Min A, Peppercorn J, S/GSK1349572 thorough QT/QTc study: a single supratherapeutic dose of S/GSK1349572 does not prolong the QTcF interval [abtract No. A1-2014]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010
   Google Scholar
• A study to evaluate the effect of GSK1349572 on iohexol and para-aminohippurate clearance in healthy subjects. Available from: http://clinicaltrials.gov/ct2/show/NCT01214993 [Last accessed 15 October 2010]
   Google Scholar
• GSK press release issued 21 July 2009, Cape Town, South Africa. Available from: http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10080.htm [Last accessed 20 October 2010]
   Google Scholar
• GSK press release issued 16 April 2009, London UK & Philadelphia, US. Available from: http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10041.htm [Last accessed 20 October 2010]
   Google Scholar
• ViiV Healthcare press release issued 22 July 2010, Vienna, Austria. Available from: http://www.viivhealthcare.com/media-room/press-releases/2010-07-22.aspx [Last accessed 20 October 2010]
   Google Scholar
• Fransen S, Gupta S, Danovich R, Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009;83(22):11440-6
   PubMed Web of Science ®Google Scholar
• Delelis O, Malet I, Na L, The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 2009;37(4):1193-201
   PubMed Web of Science ®Google Scholar